A Case of Steven-Johnson Syndrome Induced by Nivolumab

DOI
  • Hirota Nanako
    Department of Dermatology, Kindai University Faculty of Medicine
  • Suzuki Midori
    Department of Dermatology, Kindai University Faculty of Medicine
  • Kato Maiko
    Department of Dermatology, Kindai University Faculty of Medicine
  • Yanagihara Shigeto
    Department of Dermatology, Kindai University Faculty of Medicine
  • Endo Hideki
    Department of Dermatology, Kindai University Faculty of Medicine
  • Oiso Naoki
    Department of Dermatology, Kindai University Faculty of Medicine
  • Kawada Akira
    Department of Dermatology, Kindai University Faculty of Medicine
  • Otsuka Atsushi
    Department of Dermatology, Kindai University Faculty of Medicine
  • Tanaka Kaoru
    Department of Medical Oncology, Kindai University Faculty of Medicine
  • Fujita Takeshi
    Department of Otolaryngology, Kindai University Faculty of Medicine

Bibliographic Information

Other Title
  • ニボルマブによる Stevens-Johnson 症候群の 1 例

Search this article

Abstract

<p>A 64-year-old Japanese woman wasreferred to uswith erosionson the lipsand erythematous macules on the trunk and extremities. She had undergone right lateral temporal bone resection,postoperative radiation therapy, and chemotherapy for the right external auditory canal cancer one year before. The eruptionsoccurred 12 daysafter administering nivolumab for recurrence. The eruptions were diagnosed as nivolumab-induced Stevens-Johnson syndrome, an immune-related adverse event with clinical and histopathological features. The lesions were cured after applying steroid pulse therapy, plasma exchange, and intravenous immunoglobulin. To date, six cases of Stevens-Johnson syndrome and one case of toxic epidermal necrosis due to nivolumab have been reported in Japan. To prevent poor prognosis due to nivolumab-associated immune-related adverse events, immediate diagnosis and intensive treatment are required. It would be necessary to accumulate similar case series to establish appropriate management for nivolumab-induced severe immune-related adverse events. Skin Research, 21 : 1-5, 2022 </p>

Journal

  • Hifu no kagaku

    Hifu no kagaku 21 (1), 1-5, 2022

    Meeting of Osaka Dermatological Association/Meeting of Keiji Dermatological Association

Keywords

Details 詳細情報について

Report a problem

Back to top